CMBA
MACK

C.M. Bidwell & Associates’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

C.M. Bidwell & Associates’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,956
Closed -$204K – 273
2014
Q3 		$204K Buy
+2,956
New +$158K 0.05% 149

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

C.M. Bidwell & Associates's MACK Position: Q4 2014 in Review

C.M. Bidwell & Associates sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2014, closing a stake of 2,956 shares — an estimated $204K sold.

C.M. Bidwell & Associates first reported a position in MACK in Q3 2014 and held it in 1 quarter. The position peaked at $204K in Q3 2014. 143 funds tracked by Wall St. Rank hold MACK as of Q4 2014.

  • C.M. Bidwell & Associates reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 2,956 Merrimack Pharmaceuticals, Inc. shares in Q4 2014, an estimated $204K.
  • C.M. Bidwell & Associates first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Merrimack Pharmaceuticals, Inc. position peaked at $204K in Q3 2014.
  • 143 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2014.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2014, filed 9 Feb 2015.